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;jJ ence of psychoanalysis and related psychological; approaches on the treatment of schizophrenic patients l :
has waned. There are formidable intricacies involved;: in developing appropriate measures of change specifi-.;c ally relevant to the aims of psychotherapy, and until 'r ecently little attention has been paid to such assess-: ment problems (4) (5) (6) (7) (8) . Thus. for example. it is possible) to demonstrate that drugs are more effective than psy-J chotherapy in reducing a paranoid patient's bellig-j erency. but there is no way to assess the effectiveness~:1 of either mode of treatment on this palient's capacityf or i n t i m a c y . i Pharmacological treatment of schizophrenia is ex-}; traordinarily important in psychiatry. We bel ieve, how-! ever, that the treatment of schizophrenia has becomes o extensively drug oriented that a significant impediment has a,:isen to the exploration of alternati ve therapeutic approaches. The situation has reversed from;lt he 1950s, when a commitment to psychological treat-'m ent philosophies posed a serious resistance to phar-t macological innovations. Klein (9) has noted that the A automatic and immediate administration of neurolep-' tics to disturbed patients often precedes and precludes even a diagnostic evaluation. This widespread and premature foreclosure on the optimal treatment of schizophrenia is reflected by the fact that millions of people take neuroleptics as the only important component of their treatment. "
LIMITATIONS IN KNOWLEDGE OF SCHIZOPHRENIA
This narrowing of our clinical approach is especiallyã larming considering how little we know about schizoq phrenia. These limitations include the following:
I. We know virtually nothing about the etiology 0 schizophrenia. Despite evidence for a genetic contrib tion in some forms of schizophrenia, we know nothi about the nature of this component, how it may con tribute to vulnerability, or to what extent it account for the variance in manifest schizophrenia. At present Revised version of a paper presented at the 128th annual meeting of the American Psychiatric Association, Anaheim, Calif., May 5-9, 1975 .
FOR MANY understandable and good reasons, psychopharmacology is now preeminent in the treatment of schizophrenic patients. Drug administration reduces psychotic symptoms, dulls the pain of anguished patients, renders hospitalized patients dischargeable, and maintains patients in the community. It provides a rational and effective mode by which the physician can induce desired changes in his patient well within the context of the medical model.
Psychiatry's receptivity to the use of psychopharmacology in the treatment of schizophrenic patients has been enhanced by studies documenting the effectiveness of drugs while failing to find any impressive evidence for the effectiveness of psychological therapies (1) (2) (3) . However, these important studies have shortcomings and are regarded by some as an unsatisfactory test of psychotherapeutic efficacy.
On the other hand, we have little systematic information about psychotherapy (4). Psychotherapeutic ap-no factor can be said to be a necessary and sufficient cause of schizophrenia, or even necessary but insufficient.
2. Difficult diagnostic issues and patient heterogeneity limit the interpretation of data from any study of schizophrenic patients.
3. The assessment techniques that measure course and outcome in schizophrenia have serious shortcomings, especially as applied in studies comparing treatment effects.
Recognition of the paucity of etiological knowledge about schizophrenia is important since psychiatrists often assume that a rea~onedunderstanding of its cause does exist, lacking only in detail. In fact, no other disorder in the history of psychiatry has had a richer panoply of global claims to its cause and cure. Recognition of our ignorance is important because, as common sense suggests and Soskis (10) has demonstrated, etiological assumptions influence a physician's choice of treatment modality.
The second point-the problem of diagnostic shortcomings-is widely acknowledged but rarely addressed in study designs evaluating treatment modalities. Thus a group of patients who are called schizophrenic but who lack descriptive (let alone etiological) homogeneity are often studied for treatment response, and the study results are generalized as though schizophrenia were a single illness (II).
The third point-inadequacies in the assessment of course and outcome-is the least well recognized but perhaps the mo~t crucial. There are many dimensions to a patient's fate, and the effect of treatment on a patient's course cannot be adequately determined unless this complexity is taken into account. The capacity to relate socially is not the same as the capacity to hold a job, and neither of these factors can be predicted by assessing the patient's symptom picture or the necessity for hospitalization. However, all too frequently the effect of treatment on outcome is determined by measuring unitary dimensions such as the length of hospital stay. Docherty (12) reviewed the literature on maintenance drug therapy in schizophrenia and found that only 4 of 31 studies measured the effectiveness of drug therapy on dimensions other than symptom relapse or rehospitalization. While these measures/arcr vitally important, they fall drastically short of a comprehensive assessment of the patient's functioning,.fhis point was documented using 2-year follow-J.lp')~ssessmentsof 85 schizophrenic patients we evaluated as part of the Int~mational Pilot Study of Schizophrenia (IPSS) (13) . There were only modest associations between 4 out-:;ome variables, i.e., time in hospital, social function, work function, and symptoms (14) . Furthermore, the issociation between any I of these measures at 2-year "allow-up and the other measures at 5-year follow-up Nas minimal, and in some cases negligible (I5). For exlmple, assessing hospital status during a 2-year followIp gives minimal information abollt social or work 'unction at 5-year follow-up. Schwartz and asso-CARPENTER, MCGLASHAN, AND STRAUSS ciates (16) also found discordance between 4 outcome measures, i.e., mental status, social and role functioning, rehospitalization, and satisfaction with treatment. Studies assessing the relationship between treatment and outcome are severely limited unless they are based on multiple outcome dimensions.
The paucity of long-range follow-up studies also restricts our understanding of the effects of pharmacological treatment. Most reports focus on changes in the patient during hospital stay or brief follow-up periods, and few studies go beyond 2 years. Engelhardt (17) has called attention to the diminishing differences (from clinical assessment) between drug-and placebotreated patients as their course is followed over a longer period of time. This does not lessen the importance of the short-term effects of drugs, but it does suggest that we know very little about their comparative longterm advantages.
ISSUES CONCERNING DRUG TREATMENT
It is often assumed that noxious side effects of neuroleptic treatment of schizophrenia are limited to unpleasant autonomic alterations, extrapyramidal effects, rare allergies, and infrequent tardive dyski-I nesias. Recent evidence (18) (19) (20) has more carefully documented the relationship between drug treatment and the inducement or reinforcement of defect or negative symptoms (e.g., anhedonia, social isolation, postpsychotic depression, and amotivational syndromes). Nevertheless, relatively scant attention has been paid to this problem or to possible later effects of long-term drug use on affect modulation, communication, perception, or other central nervous system functions. In addition, little notice has been given to the so-called secondary side effects, such as the impact on a child's development should his mother be on long-term heavy medication. This results in a situation not entirely dissimilar to that of past enthusiasm for lobotomies, when attention focused on the positive attributes of the procedure to such a degree that the short-and long-term hazards were overlooked.
Two recent review articles have suggested that the unequivocal acceptance of neuroleptic therapy in schizophrenia is being reexamined. Tn a review of maintenance drug therapy Davis (2l) pointed out that there is a subgroup of schizophrenic patients who should not be treated with neuroleptics. Criteria for identifying this subgroup are not yet established. Furthermore, Davis believes that most patients on chronic maintenance therapy deserve a trial of withdrawal from drugs; this has the potential of enhancing the clinical course as well as reducing the risk of neurological complications. Davis is joined in this argument by Gardos and Cole (22) , who have stated that "every chronic schizophrenic outpatient maintained on antipsychotic medication should have the benefit of an adequate trial without drugs" (p. 35). Based on their review, these authors predicted that as many as 50% of all med- The ascendancy of drug treatment in schizophrenia has been accompanied by an emphasis on short-term crisis management, rapid discharge from the hospital, and community-oriented services. These trends spring from a recognition of the negative effects of chronic institutionalization and from frustration with lengthy psychotherapeutic procedures. These trends may have gone to extremes; the wisdom of early discharge and return to the community, for example, is beginning to be questioned (23, 24) .
Together, these factors have led to the following 5 prevalent and understandable, but erroneous, assumptions:
l. The schizophrenic patient must be treated with drugs and failure to do so is unethical.
2. Such patients must be maintained on drugs after symptomatic recovery.
3. Relapse must be prevented since the psychotic state is, in itself. pathogenic and actively nurtures a deteriorating course.
4. No major treatment emphasis besides drugs is essential for schizophrenics.
5. There are relatively few hazards in using medication.
Although we regard these 5 assumptions as unwarranted, we do not subscribe to opposite conclusions. Answers to these problems must be derived from careful scientific study. Our argument is that current treatment attitudes far outdistance their informational base. The polemics often introduced into discussions of treatment do not reflect scientific fact. However, issues at the interface of pharmacotherapy and psychotherapy were intelligently discussed in a recent report by the Group for the Advancement of Psychiatry (25). It seems apparent that our profession should encourage the continued evaluation of reasoned and innovative treatment approaches for schizophrenia.
THE STUDY
In this paper we describe a hospital program for acute schizophrenic patients that emphasizes psychosocial treatment and sharply limits the use of medication. The course of patients so treated is examined and contrasted with that of similar patients treated in other hospital facilities: This is not a comparative outcome study using controlled therapeutic protocols. Rather, we use available data to address one central question: does withholding medication in the context of psychosocial treatment bias against a favorable outcome in acute schizophrenia? .
METHOD
Our program was established on an II-bed clinical research unit in the National Institutes of Health (NIH) Clinical Center designed to investigate the relationship between diagnostic and psychobiological variables. We selected patients with flagrant psychotic breaks but with reasonably adequate social and work function prior to the onset of their psychotic episodes. While this was generally not their first psychotic episode, most of the patients could be considered acute or subacute schizophrenics. Informed consent was obtained from all patients after the nature of the treatment/research program was fully explained.
At admission the patients were removed from all medication for 3 weeks. Toward the end of this 3-week period a battery of psychobiological, clinical assess-.m ent, and psychophysiological research procedures was undertaken. The patients had a maximum hospitalization of 4V2 months; the average stay was slightly less than 4 months (117 days). If the patients were placed on drugs after initial testing, they repeated the 3-week drug-free period to permit research retesting prior to discharge. After discharge testing the patients were hospitalized as necessary for 2 weeks to permit reinstitution of medication and reintegration into the community. Initial follow-up evaluations were conducted 1 year after admission.
Therapeutic Environment
The therapeutic philosophy was that self-under-" standing and social adaptation are fundamental to the .p rocess of recovering from psychotic episodes. i
Patients were seen in psychoanalytically oriented psy-'; chotherapy 2-3 times a week. All patients participated J in group psychotherapy once a week and most patientsf also had family therapy once weekly. Self-understand.i:; ing was emphasized in these sessions; psychotic mani-~' festations were regarded as reflections of intrapsychic':; conflict and repetitions of past experience. The treat<t ing psychiatrists ranged in experience from third-year:r esidency to second-year postresidency. Senior psy~~<o choanalysts experienced in the treatment of schizo-~: phrenic patients provided weekly supervision.
"
Social adaptation was the principal focus in the genẽ ral therapeutic milieu with the nursing staff, occupa-;{ tional therapist, recreational therapist, and others. The} staff helped patients both control and understand their!' behavior. Special emphasis was placed on clarifying" behavioral communications, helping the patient assesi his effect on others, and exploring alternative express ions of impulses and ideas. This aspect of the thera:' peutic work was carried out in the informal conta~t; that the nursing staff had with patients as part of ordiñ ary ward life. It was also pursued on a group basis fot, 45 minutes a day at rounds where all staff and patient met to discuss issues relevant to patient care and war' 'The young psychiatrists treating the patients were not advocates'.i1f: any particular psychotherapeutic approach but were interested_l earning about the therapeutic potential of the doctor-patient rela· tionship. Most of the supervisors had worked at Chestnut Lodge.. life. This process was no doubt facilitated by the unit's small size and ample staff. The average staffing pattern included 3 psychiatrists (with both clinical and research responsibilities), 1 social worker, 1 half-time activities worker, and 13 nurses and nursing assistants (divided among 3 shifts, 7 days a week).
Brief mention should be made of our milieu approach because the question inevitably arises as to whether seriously ill, drug-free schizophrenic patients can be managed from day-to-day, let alone be treated in a therapeutic community. Jones (28) originally emphasized patient responsibility, democracy, and overlap of roles within staff and between staff and patients in a therapeutic milieu. The utility of such an approach with schizophrenic patients has come under question because these patients are often fragmented and regressed, with a poorly developed social capacity and a strong tendency toward severe withdrawal (29) .
Taking this into account, we evolved a therapeutic community organized around a clearly defined medical model. Hierarchical staff role definitions were preserved, and the psychiatrist in charge of the unit had final responsibility for the treatment program. All nembers of the community were responsible for sharng information and ideas relevant to the clinical operaion. Attendance at' ward meetings and therapeutic ses-;ions was required. This organization pr.ovided the irm external ego boundaries necessary for regressed latients, yet maximized the immense resources of the ;roup to enhance effective social intercourse, elimilate isolation, and press patients to quickly resume in-'ividual responsibility. The use of medication was ,roscribed only during the research drying-out perids; otherwise, the patient's doctor could elect to use rugs, although emphasis was always on psychosocial ·eatment. Further descriptions of this clinical pro--am have been reported elsewhere (30, 31).
'~e Two Patient Cohorts
In this report we compare the first 49 diagnosed 'hizophrenic patients admitted to the NIH research lit with 73 patients seen as part of the IPSS (13). The 'SS patients received the "usual" hospital care in 'ince Georges County, Maryland (metropolitan 'ashington, D.C.), about 1970.
2 Two of us (W.T.C. d J.S.S.) made index diagnoses in both groups folwing the descriptions and categories of DSM-IJ (32) . Ibtype diagnoses in the NIH patients were catatonic, ranoid, acute schizophrenin-eaction, and schizo-aftive schizophrenia. The 73 IPSS' patients giveñ se 4 subtype diagnoses were included in the study. so used for diagnosis was a 12-point system for idenese patients and the hospital facilities have been described elselere (30). Usual treatment involved the ubiquitous lise of neuroltic medication, Sllpport from the nursing staff, and contact with chiatrists and social workers at least weekly during hospitaltion. Psychiatrists in these facilities Were more experienced than : NIH clinical associates, but nursing staff-to-patient ratios were s favorable.
- Before reporting the results, we should again emphasize that neither the NIH program nor the IPSS was designed for treatment evaluation. In these 2 separate projects, similar clinical data were collected without any preconceived plan to compare patients. This causes certain methodological problems, and we use these data illustratively rather than definitively. One must keep in mind that "usual community care" was just that, and patients were not on controlled therapeutic protocols. NIH patients, on discharge, entered a variety of treatment settings (or none at all) but rarely received intensive psychotherapy. In fact, treatment during the follow-up period was similar for the NIH and IPSS groups. The question we address with these data is whether treating acute and subacute schizophrenic patients without drugs results in untoward outcome.
RESULTS
The study (NIH) patients and comparative (IPSS) patients were similar in important respects. Table I provides descriptive information for each sample. There were no statistically significant differences between any of the variables. Sign and symptom characteristics of all patients were determined within 10 days . after admission. The profile analysis of variance across 27 psychopathological dimensions (e.g., anxiety, audi- e. This process was no doubt facilitated by the unit's . all size and ample staff. The average staffing pattern eluded 3 psychiatrists (with both clinical and rearch responsibilities), 1 social worker, 1 half-time acvities worker, and 13 nurses and nursing assistants ivided among 3 shifts, 7 days a week). . Brief mention should be made of our milieu approach because the question inevitably arises as to whether seriously ill, drug-free schizophrenic patients can be managed from day-to-day, let alone be treated in a therapeutic community. Jones (28) originally emphasized patient responsibility, democracy, and overlap of roles within staff and between staff and patients in a therapeutic milieu. The utility of such an approach with schizophrenic patients has come under question because these patients are often fragmented -and regressed, with a poorly developed social capacity and a strong tendency toward severe withdrawal (29) . ' . Taking this into account, we evolved a therapeutic community organizec! around a clearly defined medical model. Hierarchical staff role definitions were preserved, and the psychiatrist in charge of the unit had _final responsibility for the treatment program. All :members of the community were responsible for sharing information and ideas relevant to the clinical operation. Attendance at'ward meetings and therapeutic ses-'sions was required. This organization pr.ovided the firm external ego boundaries necessary for regressed patients, yet maximized the immense resources of the group to enhance effective social intercourse, eliminate isolation, and press patients to quickly resume in-'dividual responsibility. The use of medication was proscribed only during the research drying-out peri-'ods; otherwise, the patient's doctor could elect to use drugs, although emphasis was always on psychosocial treatment. Further descriptions of this clinical program have been reported elsewhere (30,31).
. In this report we compare the first 49 diagnosed ischizophrenic patients admitted to the NIH research unit with 73 patients seen as part of the IPSS (13) . The IPSS patients received the "usual" hospital care in Prince Georges County, Maryland (metropolitan 'Washington, D.C.), about 1970.
2 Two of us (W.T.C. and J.S.S.) made index diagnoses in both groups fol-. lowing the descriptions and categories of DSM-II (32) . 'Subtype diagnoses in the NIH patients were catatonic, paranoid, acute schizophrenic reaction, and schizo-affective schizophrenia. The 73 IPSS patients given these 4 subtype diagnoses were included in the study. I~ISO used for diagnosis was a 12-point system for iden-(-"These patients and the hospital facilities have been described elseIf. where (30). Usual treatment involved the ubiquitous use of neuro-;n;' Jeptic medication, support from the nursing staff, and contact with i psychiatrists and social workers at least weekly during hospital-( Ization. Psychiatrists in these facilities were more experienced than :.:-the NIH clinical associates, but nursing staff-to-patient ratios were :::; less favorable.
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tifying schizophrenic patients (33) , the presence of Schneider's first-rank symptoms (34), and a profile analysis of variance across 27 psychopathological dimensions (35) comparing NIH and IPSS patients. Prognostic and outcome variables were assessed using schedules developed by Strauss and Carpenter (36) . Premorbid, diagnostic, and outcome data were collected using semistructured interviews developed for work in the Ipss (13, 36) (i.e., Present State Examination, Psychiatric History, and Social Description schedules).
Before reporting the results, we should again emphasize that neither the NIH program nor the IPSS was designed for treatment evaluation. In these 2 separate projects, similar clinical data were collected without any preconceived plan to compare patients. This causes certain methodological problems, and we use these data illustratively rather than definitively. One must keep in mind that "usual community care" was just that, and patients were not on controlled therapeutic protocols. NTH patients, on discharge, entered a variety of treatment settings (or none at all) but rarely received intensive psychotherapy. Tn fact, treatment during the follow-up period was similar for the NIH and IPSS groups. The question we address with these data is whether treating acute and subacute schizophrenic patients without drugs results in untoward outcome.
RESULTS
The study (NIH) patients and comparative (lPSS) patients were similar in important respects. Table I provides descriptive information for each sample. There were no statistically significant differences be-.tween any of the variables. Sign and symptom characteristics of all patients were determined within 10 days after admission. The profile analysis of variance across 27 psychopathological dimensions (e.g., anxiety, audi- TREATMENT OF ACUTE SCHIZOPHRENIA WITHOUT DRUGS tory hallucinations, restricted affect) revealed clinical similarity in both pattern and severity of symptoms. This method and the psychopathological dimensions have been previously described (35, 38) . The NIH and IPSS cohorts were also similar (i.e., not significantly different statistically) in their respective mean prognostic scores (38.3±6.5 and 37.9±5.2). The prognostic scale consisted of IS items measuring factors found by previous workers to have prognostic significance (36) . Evaluation of outcome was based on assessment of work function, social function, time spent in a hospital during the year,3 and symptoms during the month preceding follow-up evaluation. Mean outcome scores demonstrated a small but significant superiority for the NIH patients (l2.7±3.2 versus 1I.I±4.0 for the IPSS patients, p<.05, nonpaired t test).
Since some of the NIH patients received a therapeutic trial with phenothiazines, further comparisons within this cohort can be made. NIH patients treated with medication (N =22) were compared with those who were drug-free throughout their hospital stay (N =27). Mean prognostic scores were essentially the same for the drug-free and drug groups (38.6±7.3 and 38.1 ±5.3, respectively). A profile analysis of variance across 27 dimensions revealed no difference in overall pattern of psychopathology. Mean outcome scores at I year were similar for the drug-free and medicated groups (12.8±2.8 and 12.4±3.8, respectively).
Detailed longitudinal data collected on most of the NIH patients permit additional points of contrast. Average hospital stay was insignificantly longer for those patients treated with phenothiazines (126 days compared to 108 days for drug-free patients). Drug-free patients were insignificantly less likely to be rehospitalized (35% compared to 45%) or to be treated with drugs (44% compared to 67%) during the follow-up period. Patients receiving medication were significantly more likely to have a postpsychotic depression (defined in reference 20) (p<.05) and were rated as more depressed near discharge (p< .025, nonpaired t test), although they haG not been more depressed at admission (39).
A final observation involves 18 NIH patients who were being treated with drugs when their discharge was scheduled. These patients had been receiving 200-600 mg of chlorpromazine daily for an average of 46 days (range =20-65 days) when all medication was dis-"The IPSS follow-up was conducted 2 years after admission according to the plans and goals of the IPSS. The NIH project was a separate study. and initial follow-up I year after admission was designed to collect biological as well as clinical data. Since this resulted in a postdischarge period of only 8-9 months, outcome scores were extrapolated to 12 months for the time in hospital measure. Assessment of social and work function was based on the 8-to 9-month period, and symptom evaluation was based on the month prior to follow-up assessment. This discrepancy is unfortunate, but it appears to,bias outcome against the NIH patients, because 13 NIH patients were seen for a second follow-up evaluation 24-30 months after admission and had significantly better outcome scores than they had I year after admission (p< .05, paired t test). Two-year follow-up of all the NIH patients was precluded by the authors moving to other institutions.
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Am J Psychiatry 134:1, January 1977 / continued for the 3-week research test period. The other 4 drug-treated patients are omitted here since their phenothiazines were discontinued earlier for clinical' rather than research reasons. Only I of the 18 patients. withdrawn from phenothiazines showed any evidence. of clinical deterioration during this 3-week drug-free. period. In fact, many patients improved during the' drying-out period (e.g., they showed more spontaneity, fuller affect, less psychomotor retardation, and more social and work initiative). The nursing staff made daily global ratings of psychiatric illness on an 8-point scale (O=no pathology and 7=severe psychosis). Ratings were significantly lower after medication was discontinued for these 18 patients; mean ratings for the last week on drugs and the third week off drugs were 3.2 and 2.5, respectively (p<.05, paired t test). The treating physicians had tentatively planned to discharge. these 18 patients on phenothiazines, but resumed medication in only 7 of them.
DISCUSSION
The first part of this paper focused on the paucity of, knowledge regarding etiology, course, and treatment;" of schizophrenia-information gaps that should, but' do not, preclude the polarization and polemics preva~l ent in our field.
' *
In presenting our experience with a psychosociaF treatment approach, we have demonstrated that failing; to use neuroleptics during an acute psychotic episode; does not necessarily result in a disadvantageou( course and outcome, and it may have some advant ages. We have used our data to argue against statem ents to the effect that failure to use medication iiI acute schizophrenic patients is, ipso facto, unethical;; at worst or poor clinical judgment at best. Our finding; is similar to Goldstein's report, (40) of treatment advan$ tages in a subgroup of acute schizophrenic patients? when medication was withheld during the first 27 days of hospitalization and to Bockoven and Solomon's re' port (41) of comparable 5-year outcome in patienf,s treated before and after the availability of major traq u ilizers.
i ;, Considering these reports, our experience, and tr ecent reviews by Davis (21) and Gardos a~. Cole (22) , an interesting possible effect of drugs on ill course of schizophrenia emerges. Davis (21) note. that patients receiving higher dosages of neurolepti are far more likely to relapse on placebo substitutiQ than patients receiving no medication (or low dosages prior to placebo. Gardos and Cole (22) noted a tre,n from 3 studies suggesting that patients who relap while receiving drugs appear to have a higher rehg pitalization rate than patients who relapse while rec~!" ing placebo. This finding implies that relapse dutl drug administration is greater in severity than relap when no drugs are given.
:T he most plausible explanation, and the one'a" vanced by the authors of both reviews, is that t~9 ients receiVIng higher dosages of medication or , se patients relapsing while receiving neuroleptics emore severely ill. An alternative, albeit unlikely, ypothesis should at least be entertained to explain ese findings: it is possible that treatment with phenoiazine medication actually increases the risk of re-"pse. There is no question that, once patients are laced on neuroleptics, they are less vulnerable to repse if maintained on neuroleptics. But what if these tients had never been treated with drugs to begin 'th? Virtually all of the outpatient maintenance studsbegin with fully medicated patients (many of whom ave recently been discharged from the hospital) who re then divided into drug and placebo groups. These tudies usually do not include a group of patients who ave been free of drugs from the moment of their 'reakdown and hospitalization. In essence, we have ittle reliable data on the frequency of relapse during ··' e natural course of the schizophrenic process. The ockoven and Solomon study (41) relates to this queson in that one cannot simply say that before neurolep-'cs were available relapse rates were higher. 'In any case, in an illness with so many paradoxes, , raise the possibility that antipsychotic medication ymake some schizophrenic patients more vulnerIe to future relapse than would be the case in the nat-I course of their illness. Thus, as with tardive dyski-'sia, we may have a situation where neuroleptics inrease the risk for subsequent illness but must be 'aintained to prevent this risk from becoming maniest. Insofar as the psychotic break contains potential for helping the patient alter pathological conflicts with-"'himself and establish a more adaptive equilibrium "ith his environment, our present-day practice of imediate and massive pharmacological intervention ay be exacting a price in terms of producing "recov-"red" patients with greater rigidity of character struc-:\i:~~.re who are less able to cope with subsequent life resses. :There are methodological shortcomings in our dy, since a comparative investigation of treatment not the goal of the research programs. Two critical blems are the differences in timing of the follow-up valuations and the failure to control treatment in ei-"er patient group. Earlier in this paper we cited evience suggesting that the first problem probably , sed outcome against the psychosocially treated tients. Regarding the second problem, we have . ed this report on observations of "usual" treatnt in different settings. Since few patients in either hert received intensive psychosocial therapy after charge, the advantages and/or disadvantages of psybsocial treatment may be obscured by similarities in low-up treatment. Two interesting questions remain from the observa-:is on the NIH patients. What determined who re-"ed medication, and why did patients removed "'''' phenothiazines for research protocols fail to re-? With regard to the first question, our analysis aled that symptom and prognostic statuses were CARPENTER, MCGLASHAN, AND STRAUSS similar for patients who did and did not receive drugs; this suggests that variables other than clinical status (perhaps, for example, staff anxiety or treatment attitudes of the patient's psychiatrist) contributed to medication use. Consonant with this, we found that the patient's date of admission was a powerful predictor of whether or not drugs were used. The first 10 patients and 8 of the last II patients admitted to the program received drugs. We viewed this as a problem in the treatment program transition in that about 6 months were required to establish the program initially. Similarly, toward the end of the program the treatment philosophy of the unit could not be fully maintained because patients and staff anticipated a change in treatment orientation. In any case, simply knowing the date of admission and identifying patient's doctors were sufficient to predict who would receive medication. We can only speculate why patients did not relapse when drug therapy was discontinued. It is clear, however, that relapse in chronic schizophrenic patients following medication withdrawal should not be generalized to an acute schizophrenic population. In addition, increased symptoms after drug reduction during an active psychotic period should not be confused with the reappearance of psychotic symptoms (relapse) in a recovered patient. We suggest that the 17 patients who did not relapse after phenothiazine discontinuation were no longer symptomatically psychotic. Medication may have been therapeutic earlier, but it was no longer needed. The further improvement in these patients during drug withdrawal may be related to a lifting of the negative elfects of phenothiazines, with general activation ofalfect, motivation, movement, ability to experience pleasure, and social involvement.
Duri ng the 3 years of this program we systematically sought our patients' impressions regarding many aspects of the program. This was done at discharge and follow-up. These data suggest that patients found the NIH therapeutic program significantly different from programs they had participated in in other hospitals. Generally, patients reported experiencing more anguish with our treatment approach, whereas they felt a greater sense of frustration and of being "frozen in the psychosis" in settings emphasizing drug treatment. Many of the patients found their social experiences in the NIH ward both gratifying and informative, and they reported that their lives had been enhanced as a result of their therapeutic experience. A few patients made negative assessments; they felt their psychosis was destructive and their attempts to understand it were of no value. These reports highlight the importance of a continued search for subgroups of schizophrenic patients who are responsive to different therapeutic approaches.
In conclusion, our clinical observations in a biologically oriented clinical research project employing psychosocial treatment techniques argue for the feasibility of treating acute schizophrenic patients with minimal use of medication. The experience can be gratifying for patients and staff. Patients in such a program have Am J Psychiatry 134:1, JanualY 1977 not fared poorly compared with patients treated in more conventional settings. We found it possible to use a research strategy for investigating drug-free schizophrenic patients while maintaining a responsible therapeutic approach to these-patients within the framework of a medical model.
